Labcorp Gains FDA Clearance for Alzheimer's Blood Test, But Valuation Concerns Persist

What happened

Labcorp announced FDA clearance for Elecsys pTau-217, a single-biomarker blood test for Alzheimer's disease pathology, targeting individuals 55+ with cognitive decline. This test can both rule in and rule out amyloid pathology, potentially simplifying diagnosis and expanding testing beyond specialty settings to primary care. The clearance enhances Labcorp's specialty testing portfolio and aligns with its strategy to grow in neurology and precision diagnostics. However, the DeepValue master report emphasizes that Labcorp's stock is currently trading at a premium with limited margin of safety and faces reimbursement and regulatory headwinds. Consequently, while this is a positive development, it does not resolve the company's valuation concerns or execution risks, and the recommendation remains WAIT.

Implication

Investors should view this FDA clearance as a step forward in Labcorp's specialty diagnostics strategy, but the commercial impact will depend on reimbursement, adoption rates, and competitive dynamics. The test may help differentiate Labcorp in the Alzheimer's diagnostic market, but the company already has a pTau217 assay, and FDA clearance mainly broadens its potential addressable market. The master report's WAIT stance is unchanged, as the stock trades at ~26x trailing P/E and ~15.5x EV/EBITDA, well above its DCF-based intrinsic value of ~$166 per share. Key risks remain: potential PAMA/CLFS reimbursement cuts of up to 15% starting 2026, regulatory changes for lab-developed tests, and execution risk from ongoing M&A integration. Therefore, we recommend holding/waiting for a better entry point, as the current valuation lacks a margin of safety, and this news alone is insufficient to warrant a more bullish stance.

Thesis delta

The thesis remains unchanged: Labcorp is a high-quality diagnostics leader but is overvalued relative to cash flows, and this FDA clearance, while positive, does not alter the fundamental risk-reward. The addition of a first-of-its-kind FDA-cleared test strengthens the company's specialty testing moat but is unlikely to move the needle on near-term financials. We maintain a WAIT stance and would only consider upgrading on a meaningful valuation pullback or clearer evidence of commercial traction for new tests.